• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

    6/14/23 8:05:00 AM ET
    $GSK
    $PFE
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email

    Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023

    Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors

    CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat "Sath" Shukla, Spero's current Chief Financial Officer and Treasurer, will serve as Spero's President and Chief Executive Officer (CEO), and as a member of the Board of Directors, effective August 1, 2023.

    Mr. Shukla will succeed Spero's current CEO and President, Ankit Mahadevia, M.D., who will become Chairman of the Board of Directors, effective August 1, 2023. The current Chairman of the Board, Milind Deshpande, Ph.D., will remain on the Board as an independent director, and current Board member, Patrick Vink, MD., will be appointed Lead Independent Director.

    "It has been an honor to lead Spero since its inception and I am thrilled to welcome Sath as our next CEO," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. "Since its founding from a blank piece of paper, we have established Spero as a leader in serving patients with serious infections, with multiple differentiated medicines, a strong team and culture, world class partners, and a strong balance sheet. After leading the company for seven years, the Board and I believe now is the right time to begin this transition."

    Dr. Mahadevia continued, "Sath has been a key architect of the Company's growth strategy and fully embodies our mission and values. The operational experience, financial acumen, and leadership skills Sath has gained at Spero, Vertex, and other biotech companies leave him uniquely qualified to lead the next chapter of Spero's growth. Under his leadership, we will continue to work on our mission of creating solutions for patients affected by serious infections and rare diseases. I look forward to partnering with him in this endeavor. I also want to extend my gratitude to Milind Deshpande for his leadership of the Board since the Company's inception, and we are grateful for his continued service on the Board."  

    Mr. Shukla brings more than two decades of strategic and financial leadership experience to the role of CEO, including the last three years as Spero's CFO and Treasurer. During his tenure at Spero, he has led all aspects of the Company's finance, accounting, and business development functions, and has played an instrumental role in securing strategic investments and licensing agreements from GSK (NYSE:GSK) and Pfizer Inc. (NYSE:PFE).

    "It is an honor to lead Spero's world-class team of biopharmaceutical experts," said Mr. Shukla. "The closing of Spero's GSK collaboration to advance tebipenem HBr, and the progression of SPR720 into its ongoing Phase 2 clinical trial, marks a new chapter in Spero's growth strategy. Ankit's long tenure as CEO was marked by numerous important accomplishments that provide a strong foundation in the field of anti-infectives and rare diseases. I look forward to building upon this foundation, as I believe the Company is a rapidly growing, emerging leader, poised to deliver on bringing tebipenem HBr, SPR720 and SPR206 closer to those patients in need."

    "On behalf of the Board, I would like to congratulate Sath on a well-deserved promotion and welcome Ankit to his new role as Chairman," said Milind Deshpande, Ph.D., Chairman of the Board of Spero Therapeutics. "Sath and Ankit are both highly effective leaders with an impressive track record working together. I look forward to offering my continued advice and counsel to the Spero management team as an independent director and I am excited for what lies ahead for the Company."

    Spero has now launched a search for the next CFO to succeed Mr. Shukla. Until this search is completed, the Board has appointed Stephen J. DiPalma as Interim CFO and Treasurer, effective August 1, 2023.

    About Mr. Sath Shukla

    Mr. Shukla joined Spero as Chief Financial Officer (CFO) in 2020 with over two decades of strategic and financial leadership experience. During his tenure as Spero's CFO, he has led all aspects of the Company's finance, accounting, and business development functions, and has played an instrumental role in securing strategic investments and licensing agreements from GSK (NYSE:GSK) and Pfizer Inc. (NYSE:PFE). Prior to Spero, Mr. Shukla was CFO at Ziopharm Oncology, Inc. (now Alaunos Therapeutics), and prior to that, served as Vice President and Global Head of Corporate Finance for Vertex Pharmaceuticals, Inc. While at Vertex, Mr. Shukla managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing the company's entire portfolio and operations across more than 30 countries. Earlier in his career, Mr. Shukla was a Principal at Cornerstone Research, and worked for finance consulting firms LECG Corporation and Putnam, Hayes & Bartlett, Inc. Mr. Shukla earned a B.A. in Economics from Harvard University and an M.B.A. in Finance and Strategy from Yale University. He also holds the Chartered Financial Analyst designation.

    About Mr. Stephen DiPalma

    Mr. DiPalma is a Managing Director of Danforth Advisors, LLC, a financial consultancy that specializes in working with life sciences companies. Prior to and during his tenure at Danforth, Mr. DiPalma has served as interim CFO to several public and emerging companies in various stages of development. Mr. DiPalma joined Danforth in 2014 and served as CFO at Forum Pharmaceuticals from 2009 to 2014. He previously served as Spero's Interim CFO and Treasurer from November 2019 to January 2021. He holds a B.S. from the University of Massachusetts and an M.B.A. from Babson College.

    About Spero Therapeutics

    Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

    • Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
    • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
    • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

    For more information, visit https://sperotherapeutics.com.

    Forward Looking Statements

    This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the design, initiation, timing, progress and results of Spero's preclinical studies and clinical trials and its research and development programs. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intent," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether SPR720 will advance through the clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the U.S. Food and Drug Administration will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero's reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; Spero's need for additional funding; the ability to commercialize Spero's product candidates, if approved; Spero's ability to retain key personnel; Spero's ongoing leadership transitions; whether Spero's cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the "Risk Factors" set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Spero's views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero's views as of any date subsequent to the date of this press release.

    Investor Relations Contact: 

    Ted Jenkins

    Vice President, Investor Relations and Strategic Finance

    [email protected]

    (617) 798-4039

    Media Inquiries:

    Lora Grassilli, Health Media Relations

    Zeno Group

    [email protected]

    646-932-3735



    Primary Logo

    Get the next $GSK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GSK
    $PFE
    $SPRO

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    Spero Therapeutics Inc.
    $SPRO
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    Pfizer Inc.
    $PFE
    11/15/2024$25.00Underperform
    Wolfe Research
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    More analyst ratings

    $GSK
    $PFE
    $SPRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      10/31/24 4:06:54 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      12/19/23 9:31:01 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $PFE
    $SPRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      11/14/24 5:37:55 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Spero Therapeutics Inc.

      SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/24 4:25:21 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $PFE
    $SPRO
    Financials

    Live finance-specific insights

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

      Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R&D Organization On Track to Exceed Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment." Dav

      4/29/25 6:45:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Declares Second-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, develo

      4/23/25 4:40:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $PFE
    $SPRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

      Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel

      2/26/25 9:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $PFE
    $SPRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $PFE
    $SPRO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $GSK
    $PFE
    $SPRO
    SEC Filings

    See more

    $GSK
    $PFE
    $SPRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 1:49:29 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 11:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 9:37:24 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Rajavelu Esther was granted 185,000 shares, increasing direct ownership by 26% to 909,720 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      5/6/25 8:01:37 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chairman & CEO Bourla Albert

      4 - PFIZER INC (0000078003) (Issuer)

      5/2/25 1:35:56 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nora Johnson Suzanne M

      4 - PFIZER INC (0000078003) (Issuer)

      4/28/25 11:55:19 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $PFE
    $SPRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

      Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R&D Organization On Track to Exceed Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment." Dav

      4/29/25 6:45:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care